Private company

LogicBio Therapeutics, Inc.

American biological products company based in Cambridge, active since 20142

In its 2022 annual report the company says: “We are a clinical-stage genetic medicine company pioneering genome editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood. Our genome editing platform, GeneRide™, is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid, or DNA, repair process potentially leading to durable therapeutic protein expression levels.”56

Last updated Oct 20, 2026.

Overview

  • IndustryBiological Products, (No Diagnostic Substances)2
  • HeadquartersCambridge, United States2
  • Incorporated inDE3
  • Business address65 Hayden Ave, 2Nd Floor, Lexington, Ma 024213
  • Filer category, Emerging growth company3
  • Legal formCorporation2
  • LEI549300GHIQDMXT6NPC142
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O The Corporation Trust Company, 19801 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 55803672

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2021

-720.6%Operating margin4
-739.9%Net margin4
56.6%Revenue growth, 20214
-130.3%Return on equity4
0.16×Debt to equity4
-$19.8MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2021

  • Research and development96¢$28.2M
  • Interest4¢$1.1M
  • Income tax0¢$28.0K

Out of $5.4M in revenue.4 The company lost money this year.

Financial statements

Revenue4$5.4M in 2021+57% since 2020
0$2.0M$4.0M$6.0M2020: $3.5M$3.5M20202021: $5.4M$5.4M2021+57%
Operating income5674-$39.0M in 2021+566% since 2017
-$60.0M-$40.0M-$20.0M02017: -$5.9M-$5.9M20172018: -$17.9M-$17.9M2018+207%2019: -$41.0M-$41.0M2019+129%2020: -$31.5M-$31.5M2020−23%2021: -$39.0M-$39.0M2021+24%
Net income5874-$40.0M in 2021+591% since 2017
-$60.0M-$40.0M-$20.0M02017: -$5.8M-$5.8M20172018: -$17.6M-$17.6M2018+204%2019: -$40.1M-$40.1M2019+128%2020: -$32.6M-$32.6M2020−19%2021: -$40.0M-$40.0M2021+23%
Fiscal year201620172018201920202021
Revenue$3.5M4$5.4M4
Research and development$3.6M5$11.1M6$30.7M7$22.8M4$28.2M4
Operating expenses$44.4M4
Operating income-$5.9M5-$17.9M6-$41.0M7-$31.5M4-$39.0M4
Interest$2.0K6$546.0K7$1.1M4$1.1M4
Income before tax-$40.1M4
Income tax$62.0K5$86.0K6$22.0K7$188.0K4-$28.0K4
Net income-$5.8M5-$17.6M8-$40.1M7-$32.6M4-$40.0M4

Compare LogicBio Therapeutics, Inc. with another company

Corporate structure

LogicBio Therapeutics, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of LogicBio Therapeutics, Inc.

  • Beryl Capital Management LLC Filed SC 13G/A on LogicBio Therapeutics, Inc., latest Feb 14, 2023 (2 filings since Oct 13, 2022)
  • Arix Bioscience plc Filed SC 13D/A on LogicBio Therapeutics, Inc., latest Feb 10, 2023 (4 filings since Oct 26, 2021)
  • Andera Partners Filed SC 13G/A on LogicBio Therapeutics, Inc., latest Oct 20, 2022
  • Franklin Templeton Investments Filed SC 13G/A on LogicBio Therapeutics, Inc., latest Feb 4, 2022
  • LogicBio Therapeutics, Inc. Cambridge, Massachusetts, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What LogicBio Therapeutics, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$3.3M4 Dec 31, 2021$2.6M4 Dec 31, 2020+25.6%
Accumulated depreciation$1.4M4 Dec 31, 2021$809.0K4 Dec 31, 2020+71.2%
Property and equipment, net$1.9M4 Dec 31, 2021$1.8M4 Dec 31, 2020+5.3%
Operating-lease assets (leased space)$4.6M4 Dec 31, 2021$5.7M4 Dec 31, 2020−19.2%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$53.5M4 Dec 31, 2021$70.1M4 Dec 31, 2020−23.7%
Marketable securities, current$07 Dec 31, 2020$17.5M7 Dec 31, 2019−100.0%
Marketable securities, non-current$07 Dec 31, 2020$06 Dec 31, 2018

Leadership

Who has led LogicBio Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Frederic Chereau2018–2022

President

  1. Frederic Chereau2018–2022

Chief financial officer

  1. Matthias Jaffe2018–2020
  2. Cecilia Jones2021–2022
  3. Joshua Blacher2022

Chief operating officer

  1. Sandra Poole2018
  2. Kyle Chiang2020–2021
20202025
Board members and other officers (22)

Timeline

  1. Nov 16, 20228-K Ended a material agreement; Completed an acquisition or sale; Listing notice or transfer38
  2. Nov 14, 20228-K Results of operations39
  3. Oct 20, 20228-K Other events40
  4. Oct 7, 20228-K Entered a material agreement41
  5. Oct 3, 20228-K Entered a material agreement; Regulation FD disclosure; Other events42
  6. Sep 23, 20228-K Executive or director change43
  7. Sep 20, 20228-K Listing notice or transfer44
  8. Sep 16, 20228-K Executive or director change45
  9. Aug 15, 20228-K Results of operations46
  10. Jun 21, 20228-K Shareholder vote47
  11. May 16, 20228-K Results of operations48
  12. Mar 18, 20228-K Listing notice or transfer49
  13. Oct 22, 2018New chief executive Frederic Chereau becomes CEO11
  14. Aug 4, 2014Founded LogicBio Therapeutics, Inc. is founded2

Calendar

When it reported results

  1. Nov 14, 2022Reported quarterly or annual results39
  2. Aug 15, 2022Reported quarterly or annual results46
  3. May 16, 2022Reported quarterly or annual results48
  4. Mar 4, 2022Reported quarterly or annual results50
  5. Nov 15, 2021Reported quarterly or annual results51

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

74 filings to the SEC since October 2021: 2 annual reports, 4 quarterly reports, 18 major events, 28 insider forms, 8 large holders, 14 other. The latest 20:

  1. Feb 14, 2023SC 13G/A EDGAR
  2. Feb 10, 2023SC 13D/A EDGAR
  3. Nov 29, 202215-12G EDGAR
  4. Nov 18, 2022EFFECT EDGAR
  5. Nov 17, 20224 FORM 4 SUBMISSION EDGAR
  6. Nov 17, 20224 FORM 4 SUBMISSION EDGAR
  7. Nov 17, 20224 FORM 4 SUBMISSION EDGAR
  8. Nov 17, 20224 FORM 4 SUBMISSION EDGAR
  9. Nov 17, 20224 FORM 4 SUBMISSION EDGAR
  10. Nov 17, 20224 FORM 4 SUBMISSION EDGAR
  11. Nov 17, 20224 FORM 4 SUBMISSION EDGAR
  12. Nov 17, 20224 FORM 4 SUBMISSION EDGAR
  13. Nov 17, 20224 FORM 4 SUBMISSION EDGAR
  14. Nov 17, 20224 FORM 4 SUBMISSION EDGAR
  15. Nov 17, 20224 FORM 4 SUBMISSION EDGAR
  16. Nov 16, 2022SC 14D9/A EDGAR
  17. Nov 16, 2022S-8 POS EDGAR
  18. Nov 16, 2022S-8 POS EDGAR
  19. Nov 16, 2022S-8 POS EDGAR
  20. Nov 16, 2022S-8 POS EDGAR

The 74 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How LogicBio Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARLogicBio Therapeutics, Inc.1
  • CIK0001664106
  • Employer ID (EIN)47-15149751
  • Filer status<br>emerging growth company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
  • Business address65 Hayden Ave, 2Nd Floor, Lexington, MA 024211
  • Phone617-245-03991
  • Shares outstanding32,962,733 as of Nov 8, 202210
  • Public float$100.8M as of Jun 30, 20214
  • On EDGAR sinceJan 21, 20161
  • Filings290 in all: 4 (100), 8-K (52), 3 (28), 10-Q (13), SC 13G/A (9), SC 13D/A (6), SC 13G (6), 4/A (5)1
    All 44 form types

    CORRESP (5), DEFA14A (5), 10-K (4), CT ORDER (4), DEF 14A (4), S-8 (4), S-8 POS (4), UPLOAD (4), EFFECT (3), S-1/A (3), 10-K/A (2), 424B5 (2), D (2), SC 13D (2), SEC STAFF LETTER (2), 10-Q/A (1), 15-12G (1), 25-NSE (1), 3/A (1), 424B4 (1), 8-A12B (1), 8-K/A (1), CERT (1), DRS (1), DRS/A (1), DRSLTR (1), POS AM (1), POS EX (1), S-1 (1), S-3 (1), SC 14D9 (1), SC 14D9/A (1), SC TO-C (1), SC TO-T (1), SC TO-T/A (1), SC14D9C (1)

  • Latest filingsAnnual report (10-K) Mar 4, 2022
    Quarterly report (10-Q) Nov 14, 2022
    Proxy statement (DEF 14A) Apr 29, 2022
    Latest 8-K (8-K) Nov 16, 2022

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
    SEC EDGAROther events
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56